carvedilol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
vasodilators 522 72956-09-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • carvedilol
  • carvedilol phosphate
  • carvediol
  • carvedilol hydrochloride
  • carvedilol HCl
  • BM 14,190
A carbazole and propanol derivative that acts as a non-cardioselective beta blocker and vasodilator. It has blocking activity for ALPHA 1 ADRENERGIC RECEPTORS and, at higher doses, may function as a blocker of CALCIUM CHANNELS; it also has antioxidant properties. Carvedilol is used in the treatment of HYPERTENSION; ANGINA PECTORIS; and HEART FAILURE. It can also reduce the risk of death following MYOCARDIAL INFARCTION.
  • Molecular weight: 406.48
  • Formula: C24H26N2O4
  • CLOGP: 4.04
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 3
  • TPSA: 75.74
  • ALOGS: -4.96
  • ROTB: 10

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
37.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.03 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 1.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.80 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.40 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 14, 1995 FDA SMITHKLINE BEECHAM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 863.62 33.20 231 1543 20803 2335508
Hypotension 577.57 33.20 187 1587 32249 2324062
Bradycardia 499.21 33.20 129 1645 9852 2346459
Toxicity to various agents 435.54 33.20 152 1622 32602 2323709
Syncope 272.58 33.20 91 1683 16784 2339527
Drug interaction 259.11 33.20 101 1673 29062 2327249
Medication error 214.46 33.20 60 1714 6071 2350240
Dizziness 182.87 33.20 98 1676 58567 2297744
Cardiac failure 174.30 33.20 60 1714 12034 2344277
Sinus bradycardia 163.67 33.20 39 1735 2077 2354234
Overdose 152.02 33.20 62 1712 19845 2336466
Metabolic acidosis 140.27 33.20 43 1731 5955 2350356
Oedema peripheral 134.94 33.20 60 1714 23703 2332608
Drug hypersensitivity 128.54 33.20 72 1702 46571 2309740
Death 119.00 33.20 84 1690 81384 2274927
Nausea 118.11 33.20 95 1679 112094 2244217
Blood pressure increased 116.34 33.20 49 1725 16937 2339374
Dyspnoea 114.53 33.20 81 1693 78652 2277659
Fatigue 109.06 33.20 81 1693 84792 2271519
Hypertension 105.69 33.20 53 1721 27308 2329003
Atrial fibrillation 105.33 33.20 43 1731 13725 2342586
Cardiac arrest 105.32 33.20 44 1730 14886 2341425
Intentional overdose 102.73 33.20 40 1734 11281 2345030
Hyperkalaemia 99.54 33.20 33 1741 5860 2350451
Acute kidney injury 95.62 33.20 50 1724 28072 2328239
Loss of consciousness 89.41 33.20 42 1732 18725 2337586
Atrioventricular block complete 88.51 33.20 22 1752 1392 2354919
Chest pain 87.09 33.20 47 1727 28090 2328221
Headache 86.36 33.20 69 1705 80110 2276201
Palpitations 85.13 33.20 39 1735 16417 2339894
Fall 83.76 33.20 55 1719 47044 2309267
Drug ineffective 79.93 33.20 73 1701 101551 2254760
Asthenia 76.67 33.20 52 1722 46874 2309437
Blood glucose increased 69.45 33.20 31 1743 12259 2344052
Glycosylated haemoglobin increased 68.76 33.20 19 1755 1815 2354496
Dehydration 68.24 33.20 37 1737 22258 2334053
Renal impairment 65.27 33.20 28 1746 10064 2346247
Blood pressure decreased 64.30 33.20 27 1747 9209 2347102
Hypoglycaemia 63.32 33.20 26 1748 8381 2347930
Cardiac failure congestive 61.47 33.20 31 1743 16070 2340241
Orthostatic hypotension 60.30 33.20 19 1755 2860 2353451
Presyncope 59.02 33.20 20 1754 3783 2352528
Chest discomfort 58.35 33.20 29 1745 14566 2341745
Ischaemic stroke 57.21 33.20 19 1755 3378 2352933
Heart rate decreased 55.74 33.20 19 1755 3657 2352654
Weight decreased 49.96 33.20 33 1741 28338 2327973
Left ventricular hypertrophy 49.22 33.20 12 1762 699 2355612
Depressed level of consciousness 48.82 33.20 21 1753 7583 2348728
Blood creatinine increased 48.31 33.20 23 1751 10510 2345801
Hyperhidrosis 48.26 33.20 26 1748 15396 2340915
Left ventricular dysfunction 47.18 33.20 13 1761 1227 2355084
Cardiogenic shock 46.24 33.20 15 1759 2476 2353835
Acute respiratory distress syndrome 45.96 33.20 16 1758 3276 2353035
Stress cardiomyopathy 45.07 33.20 13 1761 1448 2354863
Electrocardiogram QT prolonged 45.03 33.20 20 1754 7794 2348517
Diarrhoea 45.01 33.20 49 1725 83515 2272796
Pulseless electrical activity 44.98 33.20 12 1762 1003 2355308
Urine albumin/creatinine ratio increased 44.21 33.20 7 1767 38 2356273
Circulatory collapse 44.05 33.20 16 1758 3704 2352607
Shock 42.90 33.20 16 1758 3988 2352323
Hypokalaemia 42.05 33.20 21 1753 10633 2345678
Angina unstable 41.45 33.20 12 1762 1354 2354957
Drug-induced liver injury 40.43 33.20 15 1759 3684 2352627
Diastolic dysfunction 40.24 33.20 10 1764 630 2355681
Bradyarrhythmia 40.23 33.20 9 1765 359 2355952
Torsade de pointes 39.56 33.20 13 1761 2233 2354078
Hepatic necrosis 39.30 33.20 11 1763 1099 2355212
Haemoglobin decreased 39.11 33.20 24 1750 18127 2338184
Mental status changes 37.75 33.20 16 1758 5566 2350745
Poisoning 36.66 33.20 13 1761 2807 2353504
Cough 36.48 33.20 29 1745 33088 2323223
Right aortic arch 36.46 33.20 6 1768 43 2356268
Electrocardiogram QT shortened 35.99 33.20 6 1768 47 2356264
Hepatitis 35.80 33.20 16 1758 6321 2349990
Somnolence 35.79 33.20 25 1749 23460 2332851
Mixed liver injury 35.73 33.20 8 1766 320 2355991
Heart rate increased 35.50 33.20 19 1755 11086 2345225
Suicide attempt 35.22 33.20 19 1755 11263 2345048
Condition aggravated 35.22 33.20 28 1746 31951 2324360
Exercise tolerance decreased 35.15 33.20 9 1765 640 2355671
Dry mouth 34.74 33.20 17 1757 8236 2348075
Blood pressure abnormal 34.64 33.20 11 1763 1694 2354617
Respiratory failure 34.64 33.20 20 1754 13508 2342803
Electrocardiogram repolarisation abnormality 34.60 33.20 7 1767 171 2356140
Lethargy 33.83 33.20 17 1757 8713 2347598
Arrhythmia 33.35 33.20 15 1759 6013 2350298

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 1235.05 36.78 346 2125 15966 1728344
Hypotension 1043.12 36.78 349 2122 29305 1715005
Bradycardia 896.23 36.78 246 2225 10288 1734022
Syncope 504.94 36.78 170 2301 13999 1730311
Dizziness 334.27 36.78 162 2309 34199 1710111
Cardiac failure 298.49 36.78 112 2359 12490 1731820
Hyperkalaemia 289.22 36.78 99 2372 8448 1735862
Toxicity to various agents 278.63 36.78 136 2335 29005 1715305
Dyspnoea 252.68 36.78 155 2316 51904 1692406
Drug interaction 215.62 36.78 113 2358 27845 1716465
Acute kidney injury 200.00 36.78 116 2355 34828 1709482
Orthostatic hypotension 199.13 36.78 60 2411 3371 1740939
Asthenia 174.47 36.78 106 2365 34564 1709746
Presyncope 168.70 36.78 50 2421 2648 1741662
Atrial fibrillation 142.05 36.78 70 2401 15041 1729269
Oedema peripheral 134.25 36.78 68 2403 15482 1728828
Blood pressure increased 129.13 36.78 59 2412 10694 1733616
Heart rate decreased 124.50 36.78 40 2431 2769 1741541
Drug ineffective 116.52 36.78 106 2365 63695 1680615
Atrioventricular block 110.57 36.78 31 2440 1340 1742970
Fatigue 105.78 36.78 91 2380 50690 1693620
Cardiogenic shock 104.87 36.78 34 2437 2420 1741890
Cardiac failure chronic 102.39 36.78 25 2446 623 1743687
Blood pressure decreased 98.19 36.78 44 2427 7602 1736708
Overdose 93.82 36.78 55 2416 16646 1727664
Cardio-respiratory arrest 93.00 36.78 45 2426 9248 1735062
Pulmonary oedema 91.30 36.78 40 2431 6546 1737764
Atrioventricular block complete 90.72 36.78 27 2444 1444 1742866
Ejection fraction decreased 87.42 36.78 29 2442 2216 1742094
Cardiomegaly 86.31 36.78 29 2442 2305 1742005
Cardiac failure congestive 82.35 36.78 49 2422 15221 1729089
Cardiac arrest 80.43 36.78 49 2422 15881 1728429
Chest pain 79.99 36.78 53 2418 19861 1724449
Nausea 77.76 36.78 77 2394 51119 1693191
Bradyarrhythmia 77.28 36.78 18 2453 364 1743946
Chronic kidney disease 75.71 36.78 31 2440 4286 1740024
Condition aggravated 74.73 36.78 52 2419 21098 1723212
Cough 72.06 36.78 49 2422 19148 1725162
Sinus bradycardia 71.39 36.78 24 2447 1909 1742401
Mitral valve incompetence 71.28 36.78 24 2447 1918 1742392
Nodal arrhythmia 70.96 36.78 15 2456 190 1744120
Blood creatinine increased 70.64 36.78 43 2428 13903 1730407
Loss of consciousness 70.60 36.78 44 2427 14831 1729479
Hypertension 69.12 36.78 48 2423 19400 1724910
Bundle branch block left 68.03 36.78 19 2452 808 1743502
Sinus arrest 67.58 36.78 16 2455 348 1743962
Cardioactive drug level increased 67.47 36.78 15 2456 244 1744066
Arrhythmia 65.83 36.78 31 2440 5985 1738325
Angina pectoris 64.75 36.78 29 2442 4989 1739321
Shock 63.28 36.78 27 2444 4134 1740176
Intentional product misuse 62.80 36.78 32 2439 7326 1736984
Renal impairment 62.42 36.78 38 2433 12276 1732034
Hypoglycaemia 61.46 36.78 33 2438 8405 1735905
Mouth breathing 57.33 36.78 10 2461 40 1744270
Hypovolaemia 56.29 36.78 18 2453 1222 1743088
Vertigo 55.32 36.78 25 2446 4388 1739922
Hyperhidrosis 54.37 36.78 35 2436 12453 1731857
Atrioventricular block second degree 54.13 36.78 15 2456 619 1743691
Medication error 53.60 36.78 25 2446 4718 1739592
Nodal rhythm 53.02 36.78 13 2458 329 1743981
Fall 52.81 36.78 47 2424 27167 1717143
Hypertensive crisis 52.61 36.78 18 2453 1509 1742801
Rales 52.33 36.78 16 2455 936 1743374
Dehydration 52.21 36.78 39 2432 17619 1726691
Oedema 50.10 36.78 27 2444 6921 1737389
Contraindicated product administered 49.66 36.78 17 2454 1427 1742883
Tachycardia 49.15 36.78 33 2438 12595 1731715
Troponin I increased 48.74 36.78 12 2459 309 1744001
Blood urea increased 47.62 36.78 23 2448 4688 1739622
Blood glucose increased 46.89 36.78 30 2441 10554 1733756
Somnolence 45.12 36.78 35 2436 16704 1727606
Peripheral coldness 44.96 36.78 15 2456 1163 1743147
Cardiac failure acute 44.58 36.78 15 2456 1194 1743116
Decreased appetite 43.86 36.78 40 2431 23831 1720479
Drug hypersensitivity 43.76 36.78 33 2438 15102 1729208
Respiratory arrest 42.95 36.78 23 2448 5816 1738494
Anaemia 42.13 36.78 43 2428 29414 1714896
Left ventricular dilatation 41.74 36.78 8 2463 59 1744251
Death 41.07 36.78 74 2397 87369 1656941
Blood pressure inadequately controlled 41.05 36.78 12 2459 601 1743709
Orthopnoea 40.80 36.78 12 2459 614 1743696
Blood lactic acid increased 40.59 36.78 13 2458 886 1743424
Poisoning 40.37 36.78 17 2454 2515 1741795
Arterial spasm 39.93 36.78 7 2464 29 1744281
Oesophageal discomfort 39.02 36.78 7 2464 34 1744276
Headache 38.33 36.78 44 2427 34332 1709978
Prinzmetal angina 38.30 36.78 9 2462 189 1744121
Dizziness postural 37.18 36.78 12 2459 838 1743472
Conjunctival scar 37.13 36.78 6 2465 13 1744297

Pharmacologic Action:

SourceCodeDescription
ATC C07AG02 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS
Alpha and beta blocking agents
ATC C07FX06 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS, OTHER COMBINATIONS
Beta blocking agents, other combinations
MeSH PA D018663 Adrenergic Agents
MeSH PA D058668 Adrenergic alpha-1 Receptor Antagonists
FDA MoA N0000009923 Adrenergic beta1-Antagonists
FDA MoA N0000009924 Adrenergic beta2-Antagonists
FDA EPC N0000175553 alpha-Adrenergic Blocker
FDA EPC N0000175556 beta-Adrenergic Blocker
MeSH PA D000317 Adrenergic alpha-Antagonists
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D000319 Adrenergic beta-Antagonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D000975 Antioxidants
MeSH PA D002121 Calcium Channel Blockers
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D020011 Protective Agents
CHEBI has role CHEBI:35620 vasodilator agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35530 beta-adrenergic antagonist
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:37890 alpha-adrenergic antagonist
MeSH PA D014665 Vasodilator Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Chronic heart failure indication 48447003
Left ventricular cardiac dysfunction indication 429589006
Atrial fibrillation off-label use 49436004 DOID:0060224
Diastolic heart failure off-label use 418304008 DOID:9775
Prevention of Post Cardio-Thoracic Surgery Atrial Fibrillation off-label use
Bronchospasm contraindication 4386001
Complete atrioventricular block contraindication 27885002
Sick sinus syndrome contraindication 36083008 DOID:13884
Anaphylaxis contraindication 39579001
Low blood pressure contraindication 45007003
Sinus bradycardia contraindication 49710005
Hepatic failure contraindication 59927004
Chronic bronchitis contraindication 63480004 DOID:6132
Diabetes mellitus contraindication 73211009 DOID:9351
Prinzmetal angina contraindication 87343002
Pulmonary emphysema contraindication 87433001
Cardiogenic shock contraindication 89138009
Second degree atrioventricular block contraindication 195042002
Asthma contraindication 195967001 DOID:2841
Pregnancy, function contraindication 289908002
Peripheral vascular disease contraindication 400047006
Intraoperative floppy iris syndrome contraindication 418801006
Acutely Decompensated HF Requiring Parenteral Inotropic Therapy contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.13 acidic
pKa2 7.88 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG COREG CR SMITHKLINE BEECHAM N022012 Oct. 20, 2006 RX CAPSULE, EXTENDED RELEASE ORAL 7268156 June 27, 2023 TREATMENT OF CONGESTIVE HEART FAILURE
10MG COREG CR SMITHKLINE BEECHAM N022012 Oct. 20, 2006 RX CAPSULE, EXTENDED RELEASE ORAL 7268156 June 27, 2023 TREATMENT OF HYPERTENSION
20MG COREG CR SMITHKLINE BEECHAM N022012 Oct. 20, 2006 RX CAPSULE, EXTENDED RELEASE ORAL 7268156 June 27, 2023 TREATMENT OF CONGESTIVE HEART FAILURE
20MG COREG CR SMITHKLINE BEECHAM N022012 Oct. 20, 2006 RX CAPSULE, EXTENDED RELEASE ORAL 7268156 June 27, 2023 TREATMENT OF HYPERTENSION
40MG COREG CR SMITHKLINE BEECHAM N022012 Oct. 20, 2006 RX CAPSULE, EXTENDED RELEASE ORAL 7268156 June 27, 2023 TREATMENT OF CONGESTIVE HEART FAILURE
40MG COREG CR SMITHKLINE BEECHAM N022012 Oct. 20, 2006 RX CAPSULE, EXTENDED RELEASE ORAL 7268156 June 27, 2023 TREATMENT OF HYPERTENSION
80MG COREG CR SMITHKLINE BEECHAM N022012 Oct. 20, 2006 RX CAPSULE, EXTENDED RELEASE ORAL 7268156 June 27, 2023 TREATMENT OF CONGESTIVE HEART FAILURE
80MG COREG CR SMITHKLINE BEECHAM N022012 Oct. 20, 2006 RX CAPSULE, EXTENDED RELEASE ORAL 7268156 June 27, 2023 TREATMENT OF HYPERTENSION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-2 adrenergic receptor GPCR ANTAGONIST Ki 9.90 IUPHAR CHEMBL
Beta-1 adrenergic receptor GPCR ANTAGONIST Ki 9.50 IUPHAR CHEMBL
Beta-3 adrenergic receptor GPCR ANTAGONIST Ki 9.40 IUPHAR
D(1A) dopamine receptor GPCR Ki 6.13 DRUG MATRIX
D(2) dopamine receptor GPCR Ki 7.31 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 7.40 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 6.93 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 6.27 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 8.48 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 6.93 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 7.82 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 7.22 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 6.15 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 7.37 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.71 DRUG MATRIX
Alpha-2C adrenergic receptor GPCR Ki 7.89 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 6.17 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR ANTAGONIST Ki 9.05 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR ANTAGONIST Ki 8.66 WOMBAT-PK
Solute carrier family 22 member 2 Transporter IC50 5.12 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.46 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 4.03 CHEMBL
Amyloid beta A4 protein Unclassified IC50 4.52 CHEMBL
5-hydroxytryptamine receptor 4 GPCR Ki 6.74 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 8.71 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 6.23 DRUG MATRIX
Beta-1 adrenergic receptor GPCR Ki 9.09 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 8.50 CHEMBL
Alpha-1A adrenergic receptor GPCR IC50 8.11 CHEMBL

External reference:

IDSource
D000077261 MESH_DESCRIPTOR_UI
4021041 VUID
N0000148505 NUI
C0054836 UMLSCUI
D00255 KEGG_DRUG
0K47UL67F2 UNII
5333 INN_ID
108551001 SNOMEDCT_US
4021041 VANDF
119032 MMSL
004167 NDDF
d03847 MMSL
4363 MMSL
20352 RXNORM
386870007 SNOMEDCT_US
CHEMBL723 ChEMBL_ID
610309-89-2 SECONDARY_CAS_RN
CVD PDB_CHEM_ID
DB01136 DRUGBANK_ID
CHEBI:3441 CHEBI
551 IUPHAR_LIGAND_ID
CHEMBL1201167 ChEMBL_ID
2585 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
COREG HUMAN PRESCRIPTION DRUG LABEL 1 0007-3370 CAPSULE, EXTENDED RELEASE 10 mg ORAL NDA 17 sections
COREG HUMAN PRESCRIPTION DRUG LABEL 1 0007-3371 CAPSULE, EXTENDED RELEASE 20 mg ORAL NDA 17 sections
COREG HUMAN PRESCRIPTION DRUG LABEL 1 0007-3372 CAPSULE, EXTENDED RELEASE 40 mg ORAL NDA 17 sections
COREG HUMAN PRESCRIPTION DRUG LABEL 1 0007-3373 CAPSULE, EXTENDED RELEASE 80 mg ORAL NDA 17 sections
COREG HUMAN PRESCRIPTION DRUG LABEL 1 0007-3383 CAPSULE, EXTENDED RELEASE 10 mg ORAL NDA 17 sections
COREG HUMAN PRESCRIPTION DRUG LABEL 1 0007-3385 CAPSULE, EXTENDED RELEASE 20 mg ORAL NDA 17 sections
COREG HUMAN PRESCRIPTION DRUG LABEL 1 0007-3387 CAPSULE, EXTENDED RELEASE 40 mg ORAL NDA 17 sections
COREG HUMAN PRESCRIPTION DRUG LABEL 1 0007-3388 CAPSULE, EXTENDED RELEASE 80 mg ORAL NDA 17 sections
COREG HUMAN PRESCRIPTION DRUG LABEL 1 0007-4139 TABLET, FILM COATED 3.13 mg ORAL NDA 17 sections
COREG HUMAN PRESCRIPTION DRUG LABEL 1 0007-4140 TABLET, FILM COATED 6.25 mg ORAL NDA 17 sections
COREG HUMAN PRESCRIPTION DRUG LABEL 1 0007-4141 TABLET, FILM COATED 12.50 mg ORAL NDA 17 sections
COREG HUMAN PRESCRIPTION DRUG LABEL 1 0007-4142 TABLET, FILM COATED 25 mg ORAL NDA 17 sections
Carvedilol HUMAN PRESCRIPTION DRUG LABEL 1 0093-0051 TABLET, FILM COATED 3.13 mg ORAL ANDA 17 sections
Carvedilol HUMAN PRESCRIPTION DRUG LABEL 1 0093-0135 TABLET, FILM COATED 6.25 mg ORAL ANDA 17 sections
Carvedilol HUMAN PRESCRIPTION DRUG LABEL 1 0093-7295 TABLET, FILM COATED 12.50 mg ORAL ANDA 17 sections
Carvedilol HUMAN PRESCRIPTION DRUG LABEL 1 0093-7296 TABLET, FILM COATED 25 mg ORAL ANDA 17 sections
Carvedilol HUMAN PRESCRIPTION DRUG LABEL 1 0378-3631 TABLET, FILM COATED 3.13 mg ORAL ANDA 17 sections
Carvedilol HUMAN PRESCRIPTION DRUG LABEL 1 0378-3632 TABLET, FILM COATED 6.25 mg ORAL ANDA 17 sections
Carvedilol HUMAN PRESCRIPTION DRUG LABEL 1 0378-3633 TABLET, FILM COATED 12.50 mg ORAL ANDA 17 sections
Carvedilol HUMAN PRESCRIPTION DRUG LABEL 1 0378-3634 TABLET, FILM COATED 25 mg ORAL ANDA 17 sections
Carvedilol HUMAN PRESCRIPTION DRUG LABEL 1 0615-6583 TABLET, FILM COATED 3.13 mg ORAL ANDA 18 sections
Carvedilol HUMAN PRESCRIPTION DRUG LABEL 1 0615-6584 TABLET, FILM COATED 6.25 mg ORAL ANDA 18 sections
Carvedilol HUMAN PRESCRIPTION DRUG LABEL 1 0615-6585 TABLET, FILM COATED 12.50 mg ORAL ANDA 18 sections
Carvedilol HUMAN PRESCRIPTION DRUG LABEL 1 0615-6586 TABLET, FILM COATED 25 mg ORAL ANDA 18 sections
Carvedilol HUMAN PRESCRIPTION DRUG LABEL 1 0615-7944 TABLET, FILM COATED 3.13 mg ORAL ANDA 18 sections
Carvedilol HUMAN PRESCRIPTION DRUG LABEL 1 0615-7945 TABLET, FILM COATED 12.50 mg ORAL ANDA 18 sections
Carvedilol HUMAN PRESCRIPTION DRUG LABEL 1 0615-7946 TABLET, FILM COATED 25 mg ORAL ANDA 18 sections
Carvedilol HUMAN PRESCRIPTION DRUG LABEL 1 0615-8018 TABLET, FILM COATED 6.25 mg ORAL ANDA 18 sections
Carvedilol HUMAN PRESCRIPTION DRUG LABEL 1 0781-5221 TABLET, FILM COATED 3.13 mg ORAL ANDA 17 sections
Carvedilol HUMAN PRESCRIPTION DRUG LABEL 1 0781-5222 TABLET, FILM COATED 6.25 mg ORAL ANDA 17 sections